Clinical and Economic Outcomes in Low-risk Pulmonary Embolism Patients Treated with Rivaroxaban versus Standard of Care

BACKGROUND: Rivaroxaban, a fixed-dose oral direct factor Xa inhibitor, does not require continuous monitoring and thus reduces the hospital stay and economic burden in low-risk pulmonary embolism (LRPE) patients. STUDY QUESTION: What is the effectiveness of rivaroxaban versus the standard of care (S...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Health Econ Outcomes Res
Autors principals: Peacock, W. Frank, Coleman, Craig I., Wells, Phil, Fermann, Gregory J., Wang, Li, Baser, Onur, Schein, Jeff, Crivera, Concetta
Format: Artigo
Idioma:Inglês
Publicat: Columbia Data Analytics, LLC 2019
Matèries:
Cardiovascular Conditions
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7299482/
https://ncbi.nlm.nih.gov/pubmed/32685588
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.36469/9936
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars